GLP-1 Maintenance: After You Reach Your Goal Weight
Most weight regain happens because patients stop GLP-1s too quickly. Here\'s the maintenance playbook that actually works.
The Stopping Problem
The STEP-4 trial extension showed that patients who stopped Wegovy after 20 weeks regained about two-thirds of lost weight by week 68. The drug suppresses appetite while you take it; appetite returns when you stop. Behavior change alone, in most patients, cannot hold GLP-1-magnitude losses.
Maintenance Dose Strategies
- Lower full-drug dose. Drop semaglutide from 2.4 mg → 1.0 mg/week, or tirzepatide from 15 mg → 5-7.5 mg/week. Many patients hold weight at these reduced doses with fewer side effects.
- Microdosing for maintenance. Some users transition to 0.25 mg semaglutide weekly or 1.0-2.5 mg tirzepatide. See microdosing guide.
- Less frequent dosing. Off-label: every 10-14 days instead of weekly. Limited evidence; discuss with clinician.
- Seasonal cycling. Some patients cycle on/off (e.g., 6 months on, 3 months off) — though regain risk is real.
Lifestyle Pillars for Maintenance
- Resistance training 2-3x/week — preserves lean mass, raises metabolic rate
- 1g/lb of goal weight in protein
- 10,000 steps/day baseline
- Sleep 7-9 hours
- Track weekly weight; act early if you see consistent uptrend
Frequently Asked Questions
What happens when you stop GLP-1?
Most users regain about two-thirds of lost weight within a year of stopping. The drug suppresses appetite while you take it; once stopped, appetite returns. Lifestyle alone is rarely enough to maintain GLP-1-magnitude weight loss.
GLP-1 maintenance dose after weight loss?
Many clinicians transition successful patients to a lower maintenance dose — for semaglutide, often 0.5-1.0 mg/week (vs. 2.4 mg loss dose). For tirzepatide, 5-7.5 mg/week (vs. 15 mg). This preserves loss with less side-effect burden.
Can you take GLP-1 forever?
GLP-1 medications are increasingly considered long-term treatments. Long-term safety data for liraglutide spans 15+ years; semaglutide and tirzepatide have less long-term data but trajectories look favorable.
GLP-1 weight rebound — how to prevent it?
Best practices: transition to maintenance dose rather than stopping cold; build resistance training and high-protein habits during loss phase; gradual taper if discontinuation is desired; consider seasonal cycling rather than full stop.